355 related articles for article (PubMed ID: 28417160)
21. Diagnostic performance of
Rahbar K; Afshar-Oromieh A; Seifert R; Wagner S; Schäfers M; Bögemann M; Weckesser M
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2055-2061. PubMed ID: 30027419
[TBL] [Abstract][Full Text] [Related]
22. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
[TBL] [Abstract][Full Text] [Related]
23. Targeted salvage lymphadenectomy in patients treated with radical prostatectomy with biochemical recurrence: complete biochemical response without adjuvant therapy in patients with low volume lymph node recurrence over a long-term follow-up.
Winter A; Henke RP; Wawroschek F
BMC Urol; 2015 Feb; 15(1):10. PubMed ID: 25881245
[TBL] [Abstract][Full Text] [Related]
24. PSA-stratified detection rates for [
Derlin T; Schmuck S; Juhl C; Zörgiebel J; Schneefeld SM; Walte ACA; Hueper K; von Klot CA; Henkenberens C; Christiansen H; Thackeray JT; Ross TL; Bengel FM
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):913-922. PubMed ID: 29308527
[TBL] [Abstract][Full Text] [Related]
25. Comparison of
Schollhammer R; Robert G; Asselineau J; Yacoub M; Vimont D; Balamoutoff N; Bladou F; Bénard A; Hindié E; Gallerande HC; Morgat C
J Nucl Med; 2023 Mar; 64(3):379-385. PubMed ID: 36215569
[TBL] [Abstract][Full Text] [Related]
26. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT.
Bluemel C; Krebs M; Polat B; Linke F; Eiber M; Samnick S; Lapa C; Lassmann M; Riedmiller H; Czernin J; Rubello D; Bley T; Kropf S; Wester HJ; Buck AK; Herrmann K
Clin Nucl Med; 2016 Jul; 41(7):515-21. PubMed ID: 26975008
[TBL] [Abstract][Full Text] [Related]
27. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT.
Pfister D; Porres D; Heidenreich A; Heidegger I; Knuechel R; Steib F; Behrendt FF; Verburg FA
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1410-7. PubMed ID: 26993315
[TBL] [Abstract][Full Text] [Related]
28. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
29. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
[TBL] [Abstract][Full Text] [Related]
30. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
[TBL] [Abstract][Full Text] [Related]
31. Single vial cold kits optimized for preparation of gastrin releasing peptide receptor (GRPR)-radioantagonist
Vats K; Sharma R; Kameswaran M; Satpati D; Dash A
J Pharm Biomed Anal; 2019 Jan; 163():39-44. PubMed ID: 30278325
[No Abstract] [Full Text] [Related]
32. 68Ga-RM2 PET in PSMA- positive and -negative prostate cancer patients.
Hoberück S; Michler E; Wunderlich G; Löck S; Hölscher T; Froehner M; Braune A; Ivan P; Seppelt D; Zöphel K; Kotzerke J
Nuklearmedizin; 2019 Sep; 58(5):352-362. PubMed ID: 31443113
[TBL] [Abstract][Full Text] [Related]
33. Detection Rate of
Jilg CA; Drendel V; Rischke HC; Beck TI; Reichel K; Krönig M; Wetterauer U; Schultze-Seemann W; Meyer PT; Vach W
J Nucl Med; 2019 Jul; 60(7):971-977. PubMed ID: 30683768
[TBL] [Abstract][Full Text] [Related]
34. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
35. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
[TBL] [Abstract][Full Text] [Related]
36. Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients.
Cimitan M; Evangelista L; Hodolič M; Mariani G; Baseric T; Bodanza V; Saladini G; Volterrani D; Cervino AR; Gregianin M; Puccini G; Guidoccio F; Fettich J; Borsatti E
J Nucl Med; 2015 Feb; 56(2):209-15. PubMed ID: 25552670
[TBL] [Abstract][Full Text] [Related]
37. Association between gastrin-releasing peptide receptor expression as assessed with [
Michalski K; Stoykow C; Bronsert P; Juhasz-Böss I; Meyer PT; Ruf J; Erbes T; Asberger J
Nucl Med Biol; 2020; 86-87():37-43. PubMed ID: 32473549
[TBL] [Abstract][Full Text] [Related]
38. Comparison of standard and delayed imaging to improve the detection rate of [
Schmuck S; Nordlohne S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):960-968. PubMed ID: 28280856
[TBL] [Abstract][Full Text] [Related]
39. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
[TBL] [Abstract][Full Text] [Related]
40.
Michaud L; Touijer KA; Mauguen A; Zelefsky MJ; Morris MJ; Lyashschenko SK; Durack JC; Humm JL; Weber WA; Schöder H
J Nucl Med; 2020 Jun; 61(6):827-833. PubMed ID: 31862801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]